Bringing hope through science

Notice to Annual General Meeting at Oncopeptides AB (publ)

April 16, 2025

The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.

Read more

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Exceptional long-term responses to Pepaxti – new publication in Journal of Cancer Research and Clinical Oncology

October 16, 2025

The publication of three case reports in the Journal of Cancer Research and Clinical Oncology, demonstrating long-lasting clinical responses to melflufen in patients with RRMM. Also read Q&A for investors.

Read more

New real-world data confirms efficacy and safety of Pepaxti

September 1, 2025

Two real-world studies from Spain and Italy presented at IMS 2025 show strong efficacy and favorable tolerability of Pepaxti in heavily pretreated multiple myeloma patients.

Read more

Oncopeptides announces acceptance of Spanish and Italian Real-World data at IMS Annual Meeting

July 23, 2025

Oncopeptides today announces that two real-world evidence (RWE) posters have been accepted for presentation at the upcoming International Myeloma Society (IMS) Annual Meeting, taking place in Toronto, Canada on September 17-20.

Read more